Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel

GlobeNewswire May 13, 2014

Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results

GlobeNewswire May 12, 2014

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX

PR Newswire May 5, 2014

FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel

GlobeNewswire April 30, 2014

Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel

GlobeNewswire April 14, 2014

Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis

GlobeNewswire March 17, 2014

Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2013 Financial Results

GlobeNewswire March 13, 2014

Repros Reports Findings From the Six Month Study of Androxal(R) in Men With Secondary Hypogonadism

GlobeNewswire February 10, 2014

Five Star Equities Issues New Research Reports on BIOL, OSUR, PBMD and RPRX

Accesswire February 7, 2014

Repros Meets With FDA to Discuss Data Requirements for Androxal(R) in the Treatment of Secondary Hypogonadism

Globe Newswire February 6, 2014

Pre-Market Pulse: Dendreon, Novartis AG, Stryker, and Repros Therapeutics

PR Newswire January 15, 2014

Repros Initiates Two Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel

Globe Newswire January 8, 2014

Repros Adds Marketing and Commercialization Expertise to Board of Directors

Globe Newswire December 19, 2013

Attention Repros Therapeutics, Inc. Investors: Law Firm Investigates on Behalf of Shareholders

PR Newswire December 4, 2013

Repros to Present Data on the Benefits of Testosterone Restoration With Androxal(R) Compared to T Replacement With Gels at 9th Men's Health World Congress

Globe Newswire November 25, 2013

FDA Schedules Face to Face Meeting With Repros to Discuss Androxal(R) Efficacy

Globe Newswire November 25, 2013

Repros Therapeutics Inc.(R) Reports Third Quarter 2013 Financial Results

Globe Newswire November 7, 2013

Repros Receives FDA Guidance for Proellex(R) Low Dose Oral Uterine Fibroid Clinical Program

Globe Newswire November 4, 2013

Five Star Equities Issues New Research Reports on DPS, RPRX, VAR and WYN

Accesswire October 28, 2013

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX

PR Newswire October 24, 2013